丰业银行美股招股说明书(2026-06-25版)

Filed Pursuant to Rule 424(b)(2)Registration No. 333-282565 The Bank of Nova ScotiaAutocallable Contingent Coupon Notes Due July 7, 2031 $Linked to the Least Performing of the Common Stock of Abbott Laboratories, the Common Stock of Bristol-Myers Squibb Company, the Common Stock of Johnson & Johnson and the Common Stock of McKesson Corporation General Any capitalized terms used but not defined in the following bullets have the meaning set forth under “Summary” in this pricing supplement. ￭The notes offered by this pricing supplement (the “Notes”) are unsubordinated and unsecured debt securities of The Bank ofNova Scotia (the “Bank”) and any payments on the Notes are subject to the credit risk of the Bank Payments on the Notes are based on the performance of the common stock of Abbott Laboratories, the common stock of Bristol-Myers Squibb Company, the common stock of Johnson & Johnson and the common stock of McKesson Corporation (each a “Reference Asset”), as described below The Notes will be automatically called if the Closing Value of each Reference Asset on any Call Observation Date (as specified in this pricing supplement) is equal to or greater than its Initial ValueIf the Notes are automatically called, you will receive a cash payment per Note on the Call Settlement Date equal to the Principal Amount plus the Contingent Coupon otherwise payable on the corresponding Contingent Coupon Payment Date. Following an automatic call, no further payments will be made on the Notes￭If the Notes have not been automatically called and the Closing Value of each Reference Asset on any Contingent Coupon Observation Date (as specified in this pricing supplement) is equal to or greater than its Contingent Coupon Barrier Value, theNotes will pay a Contingent Coupon (as specified under “Summary” below) on the corresponding Contingent Coupon Payment All payments on the Notes will be made in cash.Any payment on your Notes is subject to the creditworthiness of the Bank. Investment in the Notes involves certain risks. You should refer to “Additional Risks” beginning on page P-11 herein and“Additional Risk Factors Specific to the Notes” beginning on page PS-6 of the accompanying product supplement and “RiskFactors”beginning on page S-2 of the accompanying prospectus supplement and on page 8 of the accompanying The initial estimated value of your Notes at the time the terms of your Notes are set on the Trade Date is expected to bebetween $920.62 and $950.62 per $1,000 Principal Amount, which will be less than the Original Issue Price of your Noteslisted below.See “Additional Information Regarding Estimated Value of the Notes” on the following page and “Additional Risks —Risks Relating to Estimated Value and Liquidity “ beginning on page P-13 of this document for additional information. The actual value The Notes are not insured by the Canada Deposit Insurance Corporation (the “CDIC”) pursuant to the Canada Deposit Insurance Corporation Act (the “CDICAct”) or the U.S. Federal Deposit Insurance Corporation (the “FDIC”) or any other government agency of Canada, the United States or any other jurisdiction.Pricing Supplement dated [•], 2026 The Notes offered hereunder are unsubordinated and unsecured obligations of the Bank and are subject to investment risksincluding the credit risk of the Bank. As used in this pricing supplement, the “Bank,” “we,” “us” or “our” refers to The Bank of NovaScotia. The Notes will not be listed on any U.S. securities exchange or automated quotation system. The Notes are derivative products based on the price return of the Least Performing Reference Asset. All payments on the Noteswill be made in cash. The Notes do not constitute a direct investment in any of the Reference Assets. By acquiring the Notes, youwill not have a direct economic or other interest in, claim or entitlement to, or any legal or beneficial ownership of, any ReferenceAsset, including without limitation, any voting rights or rights to receive any dividends or other distributions. Our affiliate, SCUSA, may use the final pricing supplement to which this preliminary pricing supplement relates in market-makingtransactions in the Notes after their initial sale. Unless we, SCUSA or another of our affiliates selling such Notes to you informsyouotherwise in the confirmation of sale,this pricing supplement is being used in a market-making transaction.See“Supplemental Plan of Distribution (Conflicts of Interest)” in this pricing supplement and “Supplemental Plan of Distribution Additional Information Regarding Estimated Value of the Notes On the cover page of this pricing supplement, the Bank has provided the initial estimated value range for the Notes. This range ofinitial estimated values was determined by reference to the Bank’s internal pricing models, which take into consideration certainfactors, such as the Bank’s internal funding rate on the Trade Date and the Bank’s assumptions about market parameters. Formore info